ADIAL PHARMACEUTICALS, INC. - 8-K Filing
Adial Pharmaceuticals reported Q1 2026 financial results with $4.6 million in cash as of March 31, a decrease from December's $5.9 million. The company recorded R&D expenses of $433 thousand (down 42% YoY) and G&A expenses of $1.6 million (up 3% YoY), resulting in a net loss of $2.0 million for the quarter, compared to $2.2 million in Q1 2025. Adial highlighted regulatory developments that may allow FDA approval with one pivotal trial plus confirmatory evidence and is pursuing partnerships like its collaboration framework with Molteni Farmaceutici for AD04's European commercialization. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ADIL